Design, Synthesis and Biological Evaluation of α-Synuclein Proteolysis-Targeting Chimeras

Design, Synthesis and Biological Evaluation of α-Synuclein Proteolysis-Targeting Chimeras

α-Synuclein aggregation under pathological conditions is one of the causes of related neurodegenerative diseases. PROTACs (proteolysis targeting chimeras) are bifunctional small molecules that induce a post-translational erasure of proteins via the ubiquitination of target proteins by E3 ubiquitin l...

Full description

Bibliographic Details
Main Authors:	Tianzhi Wen, Jian Chen, Wenqian Zhang, Jiyan Pang
Format:	Article
Language:	English
Published:	MDPI AG 2023-05-01
Series:	Molecules
Subjects:	α-synuclein protein aggregates PROTAC (proteolysis-targeting chimera)
Online Access:	https://www.mdpi.com/1420-3049/28/11/4458

Similar Items

Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery
by: Shenxin Zeng, et al.
Published: (2021-03-01)

Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity
by: Salma Darwish, et al.
Published: (2022-07-01)

Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
by: Yujeong Moon, et al.
Published: (2023-01-01)

A Mechanistic Pharmacodynamic Modeling Framework for the Assessment and Optimization of Proteolysis Targeting Chimeras (PROTACs)
by: Robin Thomas Ulrich Haid, et al.
Published: (2023-01-01)

The clinical advances of proteolysis targeting chimeras in oncology
by: Hao Xie, et al.
Published: (2021-12-01)

MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment
by: André T. S. Vicente, et al.
Published: (2022-09-01)

Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022
by: Rekha Tamatam, et al.
Published: (2023-03-01)

Proteolysis-targeting chimeras and their implications in breast cancer
by: Angeles C. Tecalco-Cruz, et al.
Published: (2021-12-01)

Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia
by: Patrizia Porazzi, et al.
Published: (2021-08-01)

The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents
by: Bernat Coll-Martínez, et al.
Published: (2020-12-01)

Proteolysis targeting chimera technology: a novel strategy for treating diseases of the central nervous system
by: Ke Ma, et al.
Published: (2021-01-01)

Editorial: PROTACs: Targeted therapies for cancer treatment
by: Sobia Tabassum
Published: (2023-02-01)

Development of KEAP1-targeting PROTAC and its antioxidant properties: In vitro and in vivo
by: Se Yong Park, et al.
Published: (2023-08-01)

Linkers as Game-changers in PROTAC Technology: Emphasizing General Trends in PROTAC Pharmacokinetics for their Rational Design
by: Carlotta Cecchini, et al.
Published: (2022-04-01)

A Perspective on Newly Emerging Proteolysis-Targeting Strategies in Antimicrobial Drug Discovery
by: Janarthanan Venkatesan, et al.
Published: (2022-11-01)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
by: Xinyi Li, et al.
Published: (2022-04-01)

Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations
by: Pengyun Li, et al.
Published: (2023-06-01)

mRNA PROTACs: engineering PROTACs for high‐efficiency targeted protein degradation
by: Xiaoqi Xue, et al.
Published: (2024-02-01)

Synthesis and Preliminary Characterization of Putative Anle138b-Centered PROTACs against α-Synuclein Aggregation
by: Martina Pedrini, et al.
Published: (2023-05-01)

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
by: Rui Li, et al.
Published: (2022-12-01)

The Role of Proteolysis in Amyloidosis
by: Laura Acquasaliente, et al.
Published: (2022-12-01)

The Effects of Lipids on α-Synuclein Aggregation In Vitro
by: Jennifer Ramirez, et al.
Published: (2023-10-01)

Oral lipid nanocomplex of BRD4 PROteolysis TArgeting Chimera and vemurafenib for drug-resistant malignant melanoma
by: Aishwarya Saraswat, et al.
Published: (2023-12-01)

Potential application of proteolysis targeting chimera (PROTAC) modification technology in natural products for their targeted protein degradation
by: Guliang Yang, et al.
Published: (2022-03-01)

Are Therapies That Target α-Synuclein Effective at Halting Parkinson’s Disease Progression? A Systematic Review
by: Abbie T. Rodger, et al.
Published: (2023-07-01)

New Thalidomide-Resembling Dicarboximides Target ABC50 Protein and Show Antileukemic and Immunomodulatory Activities
by: Marcin Cieślak, et al.
Published: (2019-09-01)

From classic medicinal chemistry to state‐of‐the‐art interdisciplinary medicine: Recent advances in proteolysis‐targeting chimeras technology
by: Xuyang Zhao, et al.
Published: (2023-04-01)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
by: Alberto Ocaña, et al.
Published: (2020-09-01)

From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation
by: Carlotta Cecchini, et al.
Published: (2021-04-01)

De Novo Design of an Androgen Receptor DNA Binding Domain‐Targeted peptide PROTAC for Prostate Cancer Therapy
by: Bohan Ma, et al.
Published: (2022-10-01)

Targeting androgen receptor degradation with PROTACs from bench to bedside
by: Xiaojuan Jia, et al.
Published: (2023-02-01)

Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
by: Gabriel LaPlante, et al.
Published: (2021-06-01)

CK1BP Reduces α-Synuclein Oligomerization and Aggregation Independent of Serine 129 Phosphorylation
by: Lea Elsholz, et al.
Published: (2021-10-01)

Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts
by: Margaux Teil, et al.
Published: (2020-03-01)

Proteolytic α-Synuclein Cleavage in Health and Disease
by: Alexandra Bluhm, et al.
Published: (2021-05-01)

Mechanism of Anti-α-Synuclein Immunotherapy
by: Jun Sung Lee, et al.
Published: (2016-01-01)

Design, Synthesis, and Biological Evaluation of Proteolysis Targeting Chimeras (PROTACs) for the Dual Degradation of IGF-1R and Src
by: Sudhakar Manda, et al.
Published: (2020-04-01)

Recent advances in the molecular design and applications of proteolysis targeting chimera-based multi-specific antiviral modality
by: Yang Zhou, et al.
Published: (2023-08-01)

Targeted protein degradation for the treatment of Parkinson’s disease: Advances and future perspective
by: Roshanak Amirian, et al.
Published: (2023-10-01)

Effects of impaired membrane interactions on α-synuclein aggregation and neurotoxicity
by: Daniel Ysselstein, et al.
Published: (2015-07-01)